Melatonin administration Chemical structure of Melatonin Melatonin is discharged by the Pineal Gland as a neurohormone. Melatonin is a central hormone in the treatment of patients with Alzheimer's disease as it adjusts sleep patterns that are abnormal, which occurs in over forty five percent of patients. Melatonin affects<unk>  by reducing harm caused by beta amyloid, regulating hyperglycaemia and insulin resistance in patients with<unk>  and stopping blood brain barrier disruption caused by hyperglycaemia. Through these processes, melatonin has been shown to lessen the progression of<unk> . Glucagon-like Peptide 1 administration The administration of the hormone Glucagon-like Peptide 1 has shown to control the deregulation of glucose metabolism in patients with Alzheimer's disease. This hormone can recover cerebral dysfunction in<unk>  induced Alzheimer's disease. The hormone Glucagon-like Peptide 1 can lessen the brain's inflamed reaction caused by amyloid beta oxidative stress. Glucagon-like Peptide 1 can also increase the rate of neurogenesis within the brains of Alzheimer's patients. Glucagon-like Peptide 1 has the possibility to increase the production of neurons to substitute impaired neurons within the brain. This hormone can also decrease the brain's insulin resistance in Alzheimer's patients.
Type 3 diabetes
Type 3c diabetes
Type 1 diabetes
Type 2 diabetes
Prediabetes
Cystic fibrosis–related diabetes
Lifestyle causes of type 2 diabetes
Maturity onset diabetes of the young